TrialRMD open2021

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.

Karine Briot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.